Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Study Identifier:
ALXN1210-TMA-314
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Dec 2020 - Nov 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years
Requirements Information
Sex
Female & Male
Age
N/A - 17 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Dec 2020 - Nov 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years years
Requirements Information
Protocol Summary
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Trial Locations
Location
Status
Location
Research Site
Tucson, Arizona, United States, 85724
Status
N/A
Location
Research Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Research Site
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Research Site
Chicago, Illinois, United States, 60611
Status
N/A
Location
Research Site
Portland, Oregon, United States, 97239
Status
N/A
Location
Research Site
Dallas, Texas, United States, 75235
Status
N/A